Home › Certara's Synchrogenix Division Provides Unique Technology Solution, Enabling Biopharma Companies To Comply With EMA Policy 70
 

Keywords :   


Certara's Synchrogenix Division Provides Unique Technology Solution, Enabling Biopharma Companies To Comply With EMA Policy 70

2016-03-30 06:49:06| drugdiscoveryonline Home Page

Certara, the global biosimulation technology-enabled drug development company, recently announced that its regulatory and medical consultancy, Synchrogenix, has introduced an artificial intelligence (AI) -enabled solution to meet the data transparency requirements of the clinical and drug development market

Tags: policy technology unique companies

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.11Record numbers seek help with water bills
16.11 onecontrol Chamaeleo Tail Loop MKII
16.11ZIGGY ORDER-MADE
16.116
16.11SwitchCoLotta
16.11 p8
16.11mtg foil 3
16.11RolandSP-404SX
More »